Hepatic triglyceride secretion machinery

The hepatic triglyceride secretion machinery refers to the complex biological pathway responsible for the assembly and release of very low-density lipoproteins (VLDL) from the liver into the systemic circulation. This process is centered around the structural protein Apolipoprotein B-100 (ApoB) and the Microsomal Triglyceride Transfer Protein (MTP), which facilitates the loading of triglycerides and phospholipids onto the nascent lipoprotein particle within the endoplasmic reticulum. By controlling the export of lipids from the liver, this machinery plays a critical role in maintaining systemic lipid homeostasis and determining plasma levels of atherogenic lipoproteins. Dysregulation of this system is a major contributor to dyslipidemia and cardiovascular disease, while its pharmacological inhibition is used to treat severe genetic hyperlipidemias. However, blocking this machinery often leads to the accumulation of triglycerides within hepatocytes, posing a risk for the development of non-alcoholic fatty liver disease (NAFLD) and associated hepatic complications.

Other names

VLDL assembly pathwayHepatic VLDL secretion pathwayApolipoprotein B-containing lipoprotein assembly machinery

Inhibition of specific components within the machinery, such as Microsomal Triglyceride Transfer Protein (MTP) or Apolipoprotein B (ApoB) synthesis, to prevent the assembly and secretion of triglyceride-rich lipoproteins from the liver into the bloodstream.